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ABSTRACT
Background In the UK, meeting the £20 billion efﬁciency
challenge in the NHS requires new approaches to protect
quality and improve productivity. In London, clinicians,
people living with HIV and commissioners are
collaborating to reduce the cost of antiretrovirals as part
of the Quality Innovation Productivity and Prevention
agenda.
Objectives To describe how collaboration in
antiretroviral procurement in 2011/2012 aimed to
signiﬁcantly reduce drug acquisition costs, ensure equity
of prescribing and protect the quality and experience of
care and treatment for patients.
Methods Greater clinical leadership and engagement
and involvement of patient representatives enabled an
approach to drug procurement focused on clinical
outcomes at a patient and population level while
reducing cost. Consensus guidelines for implementation
were developed and agreed by all London lead clinicians
while people living with HIV produced a patient
information leaﬂet to explain the tender process and
outcomes. A planned audit is underway at all services to
monitor prescribing changes and outcomes for those on
treatment.
Results HIV clinicians, pharmacists and patient
representatives were directly involved in this novel
therapeutic tendering approach to antiretroviral drug
procurement. Modelling indicates that £8e£10 million
savings will be released through the process over
2 years.
Conclusions Clinically led therapeutic tendering of
antiretroviral drugs provides an opportunity to protect
quality and improve productivity in HIV. The approach
is novel in HIV in the UK, and the emergent learning
has implications for quality and cost improvement
in HIV spending in the UK and potentially in other
countries.
INTRODUCTION
Commissioning health services in the UK
In the UK, Primary Care Trusts (PCTs) are the
statutory bodies with responsibility for commis-
sioning health services for their patient popula-
tions. Specialised services are deﬁned in law as
those services with a planning population of >1
million people and typically include services deliv-
ered by fewer than 50 providers in England.
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Currently, the Department of Health makes
recurrent funding allocations directly to PCTs on
the basis of the relative needs of their populations
and in line with relevant policy. A weighted capi-
tation formula determines each PCT’s target share
of available resources to enable them to commis-
sion similar levels of health services for populations
in similar need and to reduce avoidable health
inequalities. In turn, PCTs work with Specialised
Commissioning Groups to agree annual budgets for
the commissioning of specialised services on their
behalf.
As a result of the wider economic climate and
rising costs of care, NHS budgets are under
unprecedented ﬁnancial pressure. The Operating
Framework for the NHS
2 sets out the requirement
to deliver up to £20 billion of efﬁciency savings by
2014/2015. In response to this challenge, the NHS
is developing Quality Innovation Productivity and
Prevention plans which aim to improve quality and
cost through innovation and effective prevention
strategies.
The challenge of commissioning for HIV care and
treatment in the UK
The epidemiology of HIV poses signiﬁcant
commissioning challenges in the context of ﬁnan-
cial constraint. According to the Health Protection
Agency, an estimated 91500 people were living
with HIV in the UK in 2010, of whom 69400 were
in care and treatment. By the end of 2012, the
number of people living with HIV infection (diag-
nosed and undiagnosed) in the UK was predicted to
have reached 100000. In addition to increases in the
number of people living with HIV, commissioning
intentions need to take account of the increasing
proportion of patients taking antiretrovirals. HIV
surveillance data indicate that in 2010, around half
of those diagnosed as having HIV infections in the
UK had a CD4 count of <350, below the recom-
mended threshold for beginning HIV treatment.
3
Current debate about the role of treatment as
prevention is likely to increase the proportion of
people on treatment further.
Additional commissioning challenges included
lack of access to patient identiﬁable data, planning
for open access to HIV services and ensuring equity
in the context of highly individualised treatments,
including the use of off-licence treatment.
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Service modelsThe London experience of commissioning for HIV care and
treatment
In London, HIV care and treatment is collaboratively commis-
sioned by the London Specialised Commissioning Group on
behalf of 31 PCTs. An engagement structure with clinically led
subgroups for Drugs and Treatment and Audit and Outcomes
bring together commissioners, clinicians and patient represen-
tatives to plan, deliver and evaluate HIV care and treatment
services. Twenty-three HIV-specialised service providers are
commissioned to deliver care and treatment services on an open
access basis.
Commissioning for improvements in quality and cost has
been underway for a number of years. London HIV care and
treatment contracts include four clinical outcome measures
related to access to care, effectiveness of treatment, effectiveness
of care and mortality. Outcomes are monitored for each provider
using Health Protection Agency surveillance data. Commis-
sioning for clinical outcomes in this way is novel and probably
unique, and the standard of clinical care achieved is interna-
tionally renowned. By 2010, the quality of HIV care received in
London was high: 80% of newly diagnosed patients were seen in
a HIV clinic within 1 month of diagnosis, 90% had an unde-
tectable viral load (<50 copies/ml) 1 year after starting therapy
and 93% of those in care for more than a year had a CD4 count
above 200 cells/mm
3.
4
In 2011/2012, the budget available to commission HIV care
and treatment in London for approximately 30000 people was
the same as the previous year at around £250 million. The
number of people living with HIV and accessing care and
treatment in London has almost doubled in the last decade and
increases annually by approximately 1800 new patients. By
2010, 83% of those in care were on antiretroviral treatment.
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A new approach to antiretroviral drug procurement: therapeutic
tendering
London NHS Trusts spend around approximately £170 million
per annum on antiretroviral drugs, representing almost 20% of
their total drugs expenditure. Antiretroviral procurement on
a collaborative pan-London basis has successfully secured equi-
table access to therapy for patients at the best-negotiated prices
for a number of years. With base case funding, commissioners
asked the clinically led Drugs and Treatment Sub Group to
consider opportunities to secure further reductions in drug
acquisition costs.
METHODS
In October 2010, the London HIV Drugs and Treatment Sub
Group agreed to include a therapeutic tender approach in the
antiretroviral procurement process for 2011/2012. The aim of
the therapeutic tender was to identify the potential for agreeing
ﬁrst-line drug choices which would stimulate volume growth
and signiﬁcantly reduce acquisition costs while protecting clin-
ical care and outcomes for all HIV-infected individuals.
Outcomes of the tender process would need to demonstrate
evidence-based use of antiretroviral drugs, in line with current
treatment guidelines, and ensure continued performance on the
London clinical outcome measures. In addition, the process
would need to support the primacy of the clinical consultation
between HIV doctor and patient. The freedom of the individual
clinician to prescribe the most appropriate drug for the patient
and full involvement of the person living with HIV in treatment
decision-making processes were conﬁrmed as fundamental
principles. On this basis, the clinicians and patient representa-
tives involved agreed that using least expensive clinically
appropriate alternatives is reasonable in order to balance the
needs of individuals and populations in a resource-constrained
environment.
The Drugs and Treatment Sub Group delegated a multidisci-
plinary panel involving doctors, commissioners, specialist phar-
macy, public health and patient representatives to take forward
the process. Meetings were held with pharmaceutical companies
to explain the process, and invitations to tender were placed in
the Ofﬁcial Journal of the European Union. Pharmaceutical
companies were invited to tender based on both continuation of
existing prescribing volumes and on a cost and volume matrix.
The procurement process was supported by the Department of
Health’s Commercial Medicines Unit.
In December 2010, tenders were reviewed by the panel and
recommendations for accepting tenders were referred to all
clinical leads for discussion and approval. Consensus prescribing
messages were developed and agreed by lead HIV clinicians for
clinically appropriate use of the least expensive nucleoside
analogue reverse transcriptase inhibitors and protease inhibitors
(PIs).
RESULTS
Clinical considerations in therapeutic tendering
HIV clinicians, commissioners and patient representatives
reviewed the submitted tenders in the context of evidence and
existing treatment guidelines, taking account of toxicity, toler-
ability and convenience. Following the review of the tenders,
there were two areas where potential changes in treatment were
agreed.
Consideration would be given ﬁrst to the use of Kivexa
(abacavir and lamivudine ﬁxed-dose combination) before teno-
fovir in the ﬁxed-dose combinations with emtricitabine
(Truvada) or with emtricitabine and efavirenz (Atripla)o r
other Nucleoside analogue Reverse Transcriptase Inhibitor
backbone combinations in patients starting antiretroviral
therapy for the ﬁrst time or where a switch of treatment was
being considered. As in the current routine clinical practice,
a negative HLA-B*5701 test would be required. Additional
exclusion criteria for using abacavir would include high baseline
viral load (>100000 copies) because of the results of the
ACTG5202 clinical trial. A high Framingham risk score for
cardiovascular disease (>10% over 10 years) would also consti-
tute an exclusion due to potential concerns about possible
cardiovascular risk with abacavir. A recent ACTG review found
no signal of enhanced cardiovascular events in individuals with
a low cardiovascular risk in randomised clinical trials. The advice
also made clear that there is a range of pre-existing abnormalities
in addition to cardiovascular risk where one nucleoside analogue
backbone might be preferred over another. While there is no
deﬁnitive data that tenofovir should not be used in individuals
with a high risk of development of renal insufﬁciency, abacavir is
often the preferred option. These recommendations are for
people starting treatment. The outcome of the tender did not
include a ﬁnancial incentive to change nucleoside treatment for
patients currently on stable treatment.
Second, with regard to PIs, a number of head-to-head studies
have demonstrated that many of the routinely used drugs have
very similar efﬁcacy proﬁles but can have different toxicity
proﬁles. Therefore, when choosing a PI for use in ﬁrst PI therapy,
it is again reasonable to take cost into account. As a result of the
tendering process, atazanavir/ritonavir offered the opportunity
for considerable cost saving if considered ﬁrst compared with
using other once-daily and twice-daily PIs.
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if some patients currently on PI-based treatment were to switch
to atazanavir/ritonavir. Therapy would be reviewed for
switching treatment but it was agreed that this would only be
considered when clinically appropriate and with the patient’s
consent.
The most recent edition of the UK (BHIVA) treatment
guidelines was published in 2008 and therefore does not capture
all current clinical practice. Clinicians involved in the process
discussed existing evidence in relation to clinical efﬁcacy and
adherence in agreeing the outcome of the tender and the
guidelines to support implementation. As >100 physicians are
involved across London in initiating or changing antiretroviral
treatment for HIV patients, the clinical guidelines were devel-
oped to ensure consistent approaches across all services. These
were widely disseminated through HIV services, the Patient and
Public Engagement Sub Group and via community information
websites including Aidsmap and HIV i-Base.
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Patient information to support the process was been crucial.
The HIV Patient and Public Engagement Sub Group developed
a leaﬂet explaining the context for the tender and the implica-
tions of the outcomes on patient care. Leaﬂets have been
disseminated via clinics and advocacy organisations.
7
Implementation and audit
Modelling suggests that the agreed contractsdwhich cover
a 2-year period from April 2011dwill deliver £8e£10 million of
savings if the volumes and prices for the antiretroviral drugs are
achieved for London as a whole. Monitoring of drug usage is
undertaken on a monthly basis and reported to clinicians at each
provider as well as being reviewed by the Drugs and Treatment
Sub Group.
Of paramount importance to commissioners, clinicians and
patients is ensuring that clinical quality of care is maintained
and clinical outcomes protected. Equity in implementation of
the clinical guidelines is also critical to success.
Providing assurance that guidelines are being implemented
and clinical outcomes protected requires a programme of audit.
All services in London are participating in an audit to track all
patients affected by the changes to monitor implementation and
the clinical outcomes. The clinically led Audit and Outcomes
Sub Group will be reviewing the audit ﬁndings over the next
2 years.
DISCUSSION AND CONCLUSIONS
The challenge for every healthcare system is how to pay for the
care it wishes to provide. The success of HIV care and treatment
means more people are living longer and healthier lives. The
continued success will depend on these and more people having
continued access to effective therapy, which must be paid for.
Everyone involveddfrom commissioners, clinical practitioners,
public health specialists, patients and their representativesd
agree on the importance of securing access to effective therapy
for the future. Finding solutions to this challenge must be
a collaborative process. This year’s work on extending the
approach to procurement of antiretrovirals is proving
successful in this regard. Modelling suggests that the work is on
target to deliver the savings required and engagement of clini-
cians and patients in procurement has been signiﬁcantly
enhanced.
One of the important tenets of medical ethics requires consid-
eration of the costs of drugs prescribed and the potential impact of
prescribing in a cost-constrained system. Suppressive HIV treat-
mentdwhatever the drug useddremains a cost-effective way
of saving years of good quality life and compares favourably
with the treatment for many other chronic diseases. Where
drugs have equivalent efﬁcacy and toxicity, prescribing the least
expensive alternative can deliver individual and public health
beneﬁt for those living with HIV.
This work has highlighted consensus on the principle that
cost is a reasonable consideration for individual clinicians and
patients to take into account when selecting treatment options
of similar efﬁcacy. Concerns have been expressed about how the
changes may affect the doctorepatient relationship. It is
essential that there is always a full discussion of treatment
options including efﬁcacy, risks and cost rationale with patients,
and this has been emphasised throughout London HIV services.
There is a strong tradition of patient engagement and advocacy
in HIV care in London and the UK which means patients,
doctors and commissioners have a history of working together
to protect quality while challenging and addressing inefﬁcien-
cies. In many London services, patients and treatment advocates
have led the way in developing or supporting improvements
such as increased peer support, more ﬂexible clinic arrangements
and home delivery of medicines.
The tender resulted in guidelines for use of preferred anti-
retrovirals that would deliver considerable cost reduction
without negatively impacting on the likely efﬁcacy or tolera-
bility of treatment, as long as the guidelines were followed. For
many patients, the newer guidelines represented potential
improvements over their previous care, often with reduced pill
burden. The outcome limited the impact on patients who were
already stable on treatment and ensured access to the highest
quality care with minimal disruption to patients. In future, it is
possible that such processes could result in tenders where less
potent antiretroviral drugs were substantially less expensive or
where savings could only be realised through more widespread
switching of patients currently on stable treatment. Both of
these issues need to be considered as part of future procurement
processes in order that quality of treatment continues to be
optimised, disruption to patients is minimised and drug acqui-
sition costs continue to improve.
For London, an important question is what will happen at the
end of this tender period. Some antiretroviral drugs have patents
due to expire. There will be new data on efﬁcacy and toxicity of
existing antiretroviral drugs and new drugs will be licensed. The
commissioning landscape too is in a process of change which
will impact on the way in which procurement exercises are
likely to be undertaken. An ongoing process of horizon scanning
will be required to inform future recommendations for drug
procurement and to continue to develop creative solutions to
manage increased demand within existing resources. While we
continue to advocate for more resources for HIV prevention, care
and treatment, we need to continue to identify opportunities for
cost improvement, so that freed up resources can be reinvested
in HIV services, and it can be shown that the current excellent
clinical care of HIV is being maintained despite ﬁnancial
constraints.
Learning points
A major challenge to the tendering process was how to engage
with all stakeholders. The commercially conﬁdential nature of
tendering restricts opportunities for consultation or the sharing
of speciﬁc details during the procurement process in order that
the outcome is not prejudiced or subject to legal challenge.
Despite the engagement achieved in the HIV therapeutic tender
through the use of clinical leads and patient representatives, the
announcement of the completed process raised some concerns
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the process.
As well as ensuring procurements continue to be Ofﬁcial
Journal of the European Union compliant, future collaborative
tendering will need to do more to communicate and reassure
stakeholders of the robustness and transparency of commercially
conﬁdential processes. For example, there would be beneﬁti n
greater discussion prior to procurements on the key objectives
and acceptability of potential outcomes. Approaches will need
to explore how to achieve greater involvement in the prepara-
tion phase, how to share non-conﬁdential information with key
groups and how outcomes can be widely publicised. Delivering
broader and deeper engagement in the context of procurement
rules requires clear structures for involvement and for decision
making, and these will need to evolve further.
In summary, reﬂections on the process so far indicate
a number of learning points, summarised in the box below.
Although the learning and outcomes for London are emergent,
indications are that collaborative approaches can secure
equitable prescribing practice, quality clinical outcomes and cost
reductions. This depends on a managed process that can achieve
clinical leadership and extensive clinical and patient engagement
in a commercially conﬁdential context. Learning from and
building on these processes will be critical if HIV is able to meet
the Quality Innovation Productivity and Prevention challenge
over the coming years.
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Key messages
< Delivering effective solutions to reducing cost and protecting
quality requires extensive and ongoing clinical engagement.
< Involvement of people living with HIV and their advocates in
Quality Innovation Productivity and Prevention plan and
procurement exercises is fundamental.
< Novel approaches in procurement can reduce drug acquisition
costs, and similar approaches could be applied to other
aspects of care and therapy.
< The London experience indicates that quality can be protected
while costs are reduced. Treatment remains in line with
guidelines, and disruption to patients has been minimised.
< Processes and outcomes need to be widely communicated
and learning used to improve future processes.
PAGE fraction trail=3.75
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